Document text
Principal Investigator: Joe H. Simmons
Organization: UNIVERSITY OF TX MD ANDERSON CAN CTR
Fiscal Year: 2021
Award: $499,948
Funding agency: NIH Office of the Director
Project Summary
Recent successes using nanoparticles encapsulating mRNA payload for COVID-19 vaccination
have energized the field of exosomes as novel vaccine agents. Exosomes (40-180nm),
extracellular vesicles of the size of a virus and shed by all cells, are actively studied in viral biology.
The reported use of exosomes to improve immunogenicity of vaccines (including SARS-Cov) may
result from their enhanced stability in vivo, tropism for immune cells, enhanced uptake and antigen
processing, and unique, virus-like presentation of a conformationally intact antigen on their
surface, a feature recognized as essential for SARS CoV-2 spike glycoprotein (SC2S)
antigenicity. Further, exosomes present with the unique property to deliver a siRNA/ASO
therapeutic payload (TP), a strategy developed at MDACC for pancreatic cancer and FDA
approved for Phase I trial (NCT03608631). Leveraging our good manufacturing practices (GMP)
certified clinical grade exosomes platform, our recent efforts in engineering and testing exosomes
presenting with surface SC2S protein aimed to yield a vaccine designed to be readily
interchangeable to other SARS, past or future. The engineered exosomes, ExoVAX-SC2S,
present SC2S on their surface and encapsulate mRNA for the spike protein. In this administrative
supplement, we will test the efficacy of ExoVAX-SC2S in eliciting B- and T cell immunity as well
as long term antibody production in Baboons. The species is best suited for testing this novel
vaccine approach due to its symptomatic presentation to SARS CoV-2 and a similar antibody
repertoire as humans. The administrative supplement coalesces the expertise of Simmons and
Kalluri laboratories to accomplish the proposed studies.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ACE2><ASO therapeutics><ASO therapy><ASO treatment><Ab response><Ad vector><Adenoviral Vector><Adenovirus Vector><Administrative Supplement><Antibodies><Antibody Formation><Antibody Production><Antibody Repertoire><Antigens><Antisense Oligonucleotide Therapy><Award><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B.1.1.7><Baboons><Binding><Binding Proteins><Biological Markers><Biology><COVID-19><COVID-19 S protein><COVID-19 infection><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 testing><COVID-19 vaccination><COVID-19 virus><COVID19><COVID19 S protein><COVID19 infection><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 testing><COVID19 vaccination><COVID19 virus><CV-19><CV19><Cell Body><Cell Line><CellLine><Cells><Clinical><CoV-2><CoV2><Cold Chains><Development><Disease><Disorder><Dose><Encapsulated><Engineering><Epithelial Cells><FDA approved><Funding><Future><Glycoproteins><Goals><Human><Immune><Immune memory><Immune response><Immunes><Immunity><Immunize><Immunologic Memory><Immunological Memory><Immunological response><Laboratories><Lead><Ligand Binding Protein><Ligand Binding Protein Gene><Logistics><Lung><Lung Respiratory System><MDACC><Malignant Pancreatic Neoplasm><Malignant neoplasm of pancreas><Messenger RNA><Mice><Mice Mammals><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Murine><Mus><Pancreas Cancer><Pancreatic Cancer><Papio><Papios><Parents><Pathway interactions><Pb element><Physiologic><Physiological><Prevention><Primates><Primates Mammals><Production><Property><Protein Binding><Proteins><Regimen><Reporting><Research Resources><Resources><Role><Route><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 S protein><SARS-CoV-2 infection><SARS-CoV-2 pathogenesis><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 testing><SARS-CoV-2 vaccination><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Savanna Baboons><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome related corona virus 2><Short interfering RNA><Small Interfering RNA><Strains Cell Lines><Surface><T-Cells><T-Lymphocyte><Testing><Therapeutic><Tropism><U.K. variant><UK variant><United Kingdom variant><University of Texas M D Anderson Cancer Center><University of Texas MD Anderson Cancer Center><Vaccine Design><Vaccines><Validation><Variant><Variation><Viral><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral Shedding><Virulent><Virus><Virus Shedding><Work><Wuhan coronavirus><adeno vector><adenovector><anamnestic reaction><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-sense oligonucleotide therapy><anti-sense therapy><antibody biosynthesis><antigen processing><antisense therapy><bio-markers><biologic marker><biomarker><bound protein><conformation><conformational state><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 testing><coronavirus disease 2019 vaccination><coronavirus disease 2019 virus><cultured cell line><develop a vaccine><development of a vaccine><developmental><efficacy testing><engineered exosomes><evaluate vaccines><exosome><extracellular vesicles><flexibility><flexible><germ free condition><hCoV19><heavy metal Pb><heavy metal lead><host response><immune system response><immunogen><immunogenicity><immunoglobulin biosynthesis><immunoresponse><improved><in vivo><in vivo evaluation><in vivo testing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><large scale production><lead candidate><mRNA><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><new vaccines><next generation vaccines><novel vaccines><pancreatic malignancy><pathway><phase 1 trial><phase I trial><preservation><pulmonary><response><secondary immune response><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 testing><severe acute respiratory syndrome-CoV><siRNA><social role><specific pathogen free><success><thymus derived lymphocyte><uptake><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine development><vaccine evaluation><vaccine formulation><vaccine screening><vaccine testing><virology><virus protein>